CLINICAL TRIALS PROFILE FOR ARRANON

All Clinical Trials for ARRANON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	Children's Cancer Group	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00005080 ↗	506U78 in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	2000-05-01	Phase II trial to study the effectiveness of 506U78 in treating patients who have lymphoma that has not been treated previously or that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
NCT00005950 ↗	506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma	Terminated	National Cancer Institute (NCI)	Phase 2	2000-04-01	Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
NCT00005982 ↗	506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma	Terminated	National Cancer Institute (NCI)	Phase 2	2000-04-01	Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma
NCT00016302 ↗	Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	N/A	2001-04-01	Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. This phase II trial is studying several different combination chemotherapy regimens to see how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia
NCT00408005 ↗	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2007-01-22	This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. After a common induction therapy, patients were risk assigned and eligible for one or both post-induction randomizations: Escalating dose Methotrexate versus High Dose Methotrexate in Interim Maintenance therapy, No Nelarabine versus Nelarabine in Consolidation therapy. T-ALL patients are risk assigned as Low Risk, Intermediate Risk or High Risk. Low Risk patients are not eligible for the Nelarabine randomization, Patients with CNS disease at diagnosis were assgined to receive High Dose Methotrexate, patients who failed induction therapy were assigned to receive Nelarabine and High Dose Methotrexate. T-LLy patients were all assigned to escalating dose Methotrexate and were risk assigned as Standard Risk, High Risk and induction failures. Standard risk patients did not receive nelarabine, High risk T-LLy patients were randomized to No Nelarabine versus Nelarabine, and Induction failures were assigned to receive Nelarabine.

Clinical Trial Conditions for ARRANON

Condition Name

Condition Name for ARRANON
Intervention	Trials
Leukemia	2
T-cell Childhood Acute Lymphoblastic Leukemia	2
Recurrent Mycosis Fungoides/Sezary Syndrome	2
Untreated Childhood Acute Lymphoblastic Leukemia	2

Condition MeSH

Condition MeSH for ARRANON
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	7
Leukemia, Lymphoid	7
Leukemia	7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	6

Clinical Trial Locations for ARRANON

Trials by Country

Trials by Country for ARRANON
Location	Trials
United States	80
Canada	11
Germany	9
Australia	8
New Zealand	2

Trials by US State

Trials by US State for ARRANON
Location	Trials
Texas	8
California	5
Illinois	4
Missouri	3
Ohio	3

Clinical Trial Progress for ARRANON

Clinical Trial Phase

Clinical Trial Phase for ARRANON
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	7
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for ARRANON
Clinical Trial Phase	Trials
Completed	6
Recruiting	3
Terminated	3

Clinical Trial Sponsors for ARRANON

Sponsor Name

Sponsor Name for ARRANON
Sponsor	Trials
National Cancer Institute (NCI)	9
GlaxoSmithKline	3
M.D. Anderson Cancer Center	3

Sponsor Type

Sponsor Type for ARRANON
Sponsor	Trials
NIH	10
Other	9
Industry	6